Company / CapEx per Share
Neurocrine Biosciences CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.34
FY2025
5-year range
$0.17 / $0.39
FY2021-FY2025
Trend
-11.6%
vs FY2024
Sector context
#33 of 190
Health Care
What the data says
Neurocrine Biosciences's capex per share of $0.34 is higher than 83% of companies in the Health Care sector (FY2025). CapEx per Share has fluctuated over the past 10 years, ranging from $0.05 in FY2016 to $0.39 in FY2024.
Based on SEC 10-K filings.
0.34 in FY2025 with a 5-year CAGR of +23.7%. Top quartile in the Health Care sector.
Improved from $0.29 to $0.34 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- +25.3%
- 5-Year CAGR
- +23.7%
- 10-Year CAGR
- -
Sector benchmark
-86.3% below sector average
Key checks
Key Insights
- In FY2025, capex per share decreased 11.6% year-over-year.
- Ranks #33 out of 190 companies in the Health Care sector.
- Peak capex per share was recorded in FY2024.
- Lowest capex per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.34 | -11.6% |
| FY2024 | $0.39 | +32.0% |
| FY2023 | $0.29 | +68.7% |
| FY2022 | $0.17 | -30.5% |
| FY2021 | $0.25 | +111.9% |
| FY2020 | $0.12 | -27.1% |
| FY2019 | $0.16 | -42.0% |
| FY2018 | $0.28 | +249.7% |
| FY2017 | $0.08 | +67.7% |
| FY2016 | $0.05 | +88.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026